Gene · 7006
Papers1,477
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,477
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Engineered multicolor "Fluorescent Lantern" TEC-Fusion protein with tunable spectra enables multiplexed fluorescent labeling and biological imaging. | Spectrochim Acta A Mol Biomol Spectrosc | 2027 | 42632270 | PubTator, text mining | PubMed |
| JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions. | Drug Des Devel Ther | 2026 | 42824469 | PubTator, text mining | PubMed |
| Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study. | Dermatol Ther (Heidelb) | 2026 | 42823604 | PubTator, text mining | PubMed |
| Mechanism and Individualized Management of Hypertension Associated With Bruton Tyrosine Kinase Inhibitors: The PCSK9/Notch3 Signaling Pathway. | Front Biosci (Landmark Ed) | 2026 | 42811994 | PubTator, text mining | PubMed |
| Success of Deuruxolitinib (Leqselvi™) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report. | Cureus | 2026 | 42529366 | PubTator, text mining | PubMed |
| Bruton Tyrosine Kinase as Therapeutic Target in Cardiovascular Diseases-Executive Summary. | Thromb Haemost | 2026 | 42419695 | PubTator, text mining | PubMed |
| Tectorigenin Protects Irradiation-Induced Injury of HUVECs by Inhibiting Mitophagy Through PINK1/Parkin Pathway. | Front Biosci (Landmark Ed) | 2026 | 42216527 | PubTator, text mining | PubMed |
| Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies. | J Enzyme Inhib Med Chem | 2026 | 42212521 | PubTator, text mining | PubMed |
| Site-Specific Phosphoproteomic Profiling of CAV1 Reveals Co-Regulatory Kinase Networks in Cancer Signaling. | Int J Mol Sci | 2026 | 42196307 | PubTator, text mining | PubMed |
| Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. | Dermatol Ther (Heidelb) | 2026 | 42171987 | PubTator, text mining | PubMed |
| Early On-Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate-To-Severe Alopecia Areata: A Real-World Cohort Study. | Int J Dermatol | 2026 | 42144845 | PubTator, text mining | PubMed |
| Structure-Aware Compound-Protein Affinity Prediction via Graph Neural Networks with Group Lasso Regularization. | Comput Struct Biotechnol J | 2026 | 42057778 | PubTator, text mining | PubMed |
| The role of JAK3 and TEC family kinases in vitiligo pathogenesis. | Front Immunol | 2026 | 41918735 | PubTator, text mining | PubMed |
| Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility. | J Mol Med (Berl) | 2026 | 41917502 | PubTator, text mining | PubMed |
| Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies. | Am J Clin Dermatol | 2026 | 41917311 | PubTator, text mining | PubMed |
| Efficient foam-based thermal interface material functionalized with MWCNTs for CPU cooling applications: thermal performance modeling and Experimental studies. | Sci Rep | 2026 | 41904159 | PubTator, text mining | PubMed |
| Discovery of Covalent Ligands with AlphaFold3. | J Am Chem Soc | 2026 | 41857796 | PubTator, text mining | PubMed |
| Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study. | Am J Clin Dermatol | 2026 | 41855013 | PubTator, text mining | PubMed |
| Treatments and Targets to Achieve Disease Control in Chronic Spontaneous Urticaria: Current and Emerging Therapeutic Options. | J Inflamm Res | 2026 | 41809769 | PubTator, text mining | PubMed |
| The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment. | Research (Wash D C) | 2026 | 41809407 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7006/papers